Alzheimer’s disease and related dementias (ADRD)


Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life.

Every 3rd senior in America dies of ADRD, accumulating more deaths than prostate and breast cancer combined.

Most common type of dementia is Alzheimer’s disease (AD) and it accounts for an estimated 60 to 80 percent of cases. There are 5,4 million Americans living with the diagnosed disease right now, for which the cost of care and treatment is $236 billion.¹

late start of treatment


Alzheimer’s disease (AD) can be diagnosed by a physicians' assessment of symptoms only at a later stage, when noticeable cognitive decline caused by severe neuronal loss has already occured.¹


Medication existing today is effective in animal models but at much earlier stage of the disease, before the symptoms of massive neuronal loss are noticeable.


Therefore the hope for prolonged cognitive function and active years of patients lies in the earlier diagnosis of the disease.


The solution in early diagnosis


The system designed by NIBS, enables  early and objective detection of subtle degeneration that predicts cognitive decline yet to come, allowing the physician an objective differentiation prognosis of dementia type, being AD, Frontal dementia, Parkinson's Disease, Multiple sclerosis, ect.


As a quick and accessible screen test for early diagnosis of ADRD, The system enables the early onset of treatment that can postpone neuro-degeneration and  prolong the patient’s cognitive capabilities.



Note: Please fill out the fields marked with an asterisk.

 For support or further information about AD and related dementias please visit the following sites:


 Alzheimer’s Foundation of America

 National Institute for Ageing